Article Versions Notes

Puig L, Shams K, Furlan F, Salvati C, Romero E, Fan J, Iversen L. Real-World Effectiveness and Safety of SDZ-ADL (Adalimumab Biosimilar) in Patients with Psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Biologics. 2022; 2(4):213-225. https://doi.org/10.3390/biologics2040017

Puig, Lluís, Kave Shams, Fabricio Furlan, Cristofer Salvati, Elisa Romero, Jamie Fan, and Lars Iversen. 2022. "Real-World Effectiveness and Safety of SDZ-ADL (Adalimumab Biosimilar) in Patients with Psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)" Biologics 2, no. 4: 213-225. https://doi.org/10.3390/biologics2040017

Puig, L., Shams, K., Furlan, F., Salvati, C., Romero, E., Fan, J., & Iversen, L. (2022). Real-World Effectiveness and Safety of SDZ-ADL (Adalimumab Biosimilar) in Patients with Psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Biologics, 2(4), 213-225. https://doi.org/10.3390/biologics2040017